| Philip Pelton, | |
|
1727 S Park St, Kalamazoo, MI 49001-2781 | |
| (269) 342-3910 | |
| (269) 342-5263 |
| Full Name | Philip Pelton |
|---|---|
| Gender | Male |
| Speciality | Optometry |
| Experience | 3 Years |
| Location | 1727 S Park St, Kalamazoo, Michigan |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1275117319 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 152W00000X | Optometrist | 4901005543 (Michigan) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Myeyedr Optometry Of Michigan, Llc | 7416288949 | 51 |
News Archive
Performing a mastoidectomy, a group of operations on the temporal bone and middle ear to drain, expose, or remove an infectious, inflammatory, or neoplastic lesion, during cochlear implantation for young children does not decrease the possibility that the young patient will develop a middle ear infection.
Liquidia Technologies today announced a collaboration with the PATH Malaria Vaccine Initiative (MVI) to explore the use of the company's PRINT® particle technology to design next generation malaria vaccines. PRINT technology offers unprecedented control of particle size, shape and chemistry in a highly consistent and scalable manufacturing process, and will be used to deliver a protein in combination with immune stimulating molecules.
POZEN Inc., a pharmaceutical company committed to transforming medicine that transforms lives, today announced the submission of a New Drug Application to the U.S. Food and Drug Administration for the marketing approval of PA32540/PA8140.
Can a very common allergy medicine improve survival among patients suffering from the serious skin cancer, malignant melanoma? A new study from Lund University in Sweden indicates that this may be the case.
› Verified 8 days ago
| Provider Name | Myeyedr Optometry Of Michigan, Llc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1639723596 PECOS PAC ID: 7416288949 Enrollment ID: O20191014002048 |
News Archive
Performing a mastoidectomy, a group of operations on the temporal bone and middle ear to drain, expose, or remove an infectious, inflammatory, or neoplastic lesion, during cochlear implantation for young children does not decrease the possibility that the young patient will develop a middle ear infection.
Liquidia Technologies today announced a collaboration with the PATH Malaria Vaccine Initiative (MVI) to explore the use of the company's PRINT® particle technology to design next generation malaria vaccines. PRINT technology offers unprecedented control of particle size, shape and chemistry in a highly consistent and scalable manufacturing process, and will be used to deliver a protein in combination with immune stimulating molecules.
POZEN Inc., a pharmaceutical company committed to transforming medicine that transforms lives, today announced the submission of a New Drug Application to the U.S. Food and Drug Administration for the marketing approval of PA32540/PA8140.
Can a very common allergy medicine improve survival among patients suffering from the serious skin cancer, malignant melanoma? A new study from Lund University in Sweden indicates that this may be the case.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Philip Pelton, 8614 Westwood Center Dr Fl 9, Vienna, VA 22182-2442 Ph: (703) 847-8899 | Philip Pelton, 1727 S Park St, Kalamazoo, MI 49001-2781 Ph: (269) 342-3910 |
News Archive
Performing a mastoidectomy, a group of operations on the temporal bone and middle ear to drain, expose, or remove an infectious, inflammatory, or neoplastic lesion, during cochlear implantation for young children does not decrease the possibility that the young patient will develop a middle ear infection.
Liquidia Technologies today announced a collaboration with the PATH Malaria Vaccine Initiative (MVI) to explore the use of the company's PRINT® particle technology to design next generation malaria vaccines. PRINT technology offers unprecedented control of particle size, shape and chemistry in a highly consistent and scalable manufacturing process, and will be used to deliver a protein in combination with immune stimulating molecules.
POZEN Inc., a pharmaceutical company committed to transforming medicine that transforms lives, today announced the submission of a New Drug Application to the U.S. Food and Drug Administration for the marketing approval of PA32540/PA8140.
Can a very common allergy medicine improve survival among patients suffering from the serious skin cancer, malignant melanoma? A new study from Lund University in Sweden indicates that this may be the case.
› Verified 8 days ago
Dr. Nicholas John Ciotti, OD Optometrist Medicare: Accepting Medicare Assignments Practice Location: 575 N Drake Rd, Kalamazoo, MI 49009 Phone: 269-382-5942 | |
Rx Optical Optometrist Medicare: Not Enrolled in Medicare Practice Location: 5349 W Main St, Kalamazoo, MI 49009 Phone: 269-349-7627 Fax: 269-349-7665 | |
Svs Vision Optical Centers Optometrist Medicare: Not Enrolled in Medicare Practice Location: 1700 S Drake Rd Ste D, Kalamazoo, MI 49006 Phone: 269-888-4320 Fax: 269-585-6259 | |
Rx Optical Laboratories, Inc Optometrist Medicare: Not Enrolled in Medicare Practice Location: 2067 South Drake Rd, Kalamazoo, MI 49006 Phone: 269-366-3664 Fax: 269-366-3665 | |
Joseph B Budge, O.D. Optometrist Medicare: Not Enrolled in Medicare Practice Location: 575 N Drake Rd, West Main Plaza, Kalamazoo, MI 49009 Phone: 616-382-5942 | |
Ford Optometry, Llc Optometrist Medicare: Not Enrolled in Medicare Practice Location: 501 N 9th St, Kalamazoo, MI 49009 Phone: 269-544-2952 | |
Rx Optical Laboratories, Inc. Optometrist Medicare: Not Enrolled in Medicare Practice Location: 1727 S Park St, Kalamazoo, MI 49001 Phone: 269-342-3910 |